Warning Letters Needed To Rein In Outlier IVD Practices – Attorney Kahan
This article was originally published in The Gray Sheet
Executive Summary
The Office of In Vitro Diagnostic Device Evaluation & Safety (OIVD) has a new program to deal with certain IVD problems on an "informal" basis, according to OIVD Director Steven Gutman
You may also be interested in...
OIVD Issues Warning Letter For Cancer Screening Software
FDA's Office of In Vitro Diagnostic Device Evaluation & Safety cited BioImagene in a May 25 FDL-1warning letter for marketing its software tool Pathiam as a diagnostic device without 510(k) clearance or marketing approval
OIVD Issues Warning Letter For Cancer Screening Software
FDA's Office of In Vitro Diagnostic Device Evaluation & Safety cited BioImagene in a May 25 FDL-1warning letter for marketing its software tool Pathiam as a diagnostic device without 510(k) clearance or marketing approval
IVD Data Integrity Concerns Are Increasingly 510(k)-Related
In vitro diagnostic device 510(k) data will be getting a closer look from FDA, following a trend toward data integrity issues in premarket submissions